KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Total Current Liabilities (2017 - 2025)

Novartis Ag's Total Current Liabilities history spans 9 years, with the latest figure at $27.3 billion for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 4.93% year-over-year to $27.3 billion; the TTM value through Dec 2025 reached $27.3 billion, down 4.93%, while the annual FY2025 figure was $27.3 billion, 4.93% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $27.3 billion at Novartis Ag, down from $28.7 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $30.2 billion in Q4 2021 and bottomed at $26.4 billion in Q4 2023.
  • The 5-year median for Total Current Liabilities is $28.7 billion (2022), against an average of $28.2 billion.
  • The largest annual shift saw Total Current Liabilities decreased 8.62% in 2021 before it increased 8.72% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $30.2 billion in 2021, then decreased by 5.14% to $28.7 billion in 2022, then dropped by 7.91% to $26.4 billion in 2023, then grew by 8.72% to $28.7 billion in 2024, then fell by 4.93% to $27.3 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Total Current Liabilities are $27.3 billion (Q4 2025), $28.7 billion (Q4 2024), and $26.4 billion (Q4 2023).